CUSTOMER: A LEADING, CLINICAL-STAGE BIOTECHNOLOGY COMPANY
This biotechnology company specializes in the discovery and development of small molecule medicines with novel modes of action. Their pipeline comprises Phase 1-3 studies, pre-clinical studies and discovery programs in inflammation, fibrosis, osteoarthritis, metabolic diseases and other indications. The company’s workforce includes more than 300 R&D specialists engaged in the discovery of breakthrough therapies for the treatment of unmet medical needs.
CHALLENGE: EXPANDING PIPELINE, MANAGING IP WITH PARTNERS
Research and Development is this company’s innovation engine. For this reason, they require a robust lab informatics infrastructure with all processes supporting a healthy product pipeline. Inefficient lab workflows and poor visibility across research data was threatening to jeopardize clinical programs, from discovery to registration and beyond. The company wanted to improve data and process standardization, automate routine activities and avoid duplicating experiments. They also wanted to secure their intellectual property (IP) and minimize the risk of confidentiality breaches, while also supporting long-term, risk-sharing collaborative partnerships with top pharma companies. To address these challenges, they needed to replace their legacy, paper-based processes with an entirely digitalized lab environment that supported the innovation lifecycle from target identification to compound discovery and process development.